Figure 2From: Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Relapse free survival for E-CMF (solid line) versus CMF (dashed line). Panel A: TIMP-1 negative tumors. Panel B: TIMP-1 immunoreactive tumors.Back to article page